Previous 10 | Next 10 |
AlloVir press release ( NASDAQ: ALVR ): Q3 GAAP EPS of -$0.50 beats by $0.03 . As of September 30, 2022, AlloVir had cash, cash equivalents, and marketable securities of $264.1 million, compared with $248.1 million as of December 31, 2021. For further details see...
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that final data from the Phase 2 study of posoleucel for the prevention of clinically significant infections or diseases by multiple viruses following allogeneic hematopoietic ce...
Posoleucel Continues to Advance in Three Ongoing Multi-National Phase 3 Registrational Trials Final Data Presentation from Posoleucel Phase 2 Multi-Virus Prevention Study by Year-End Company to Host Investor Webcast on December 14 with Clinical Trial Investigators on P...
AlloVir, Inc. ( NASDAQ: ALVR ) dropped ~15% intraday on Monday after regulatory filings indicated that the Executive Chairman of the cell therapy company David Hallal sold more than $5M worth of ALVR stock he has indirectly owned. The SEC Form 4 submitted by Hallal sho...
The following slide deck was published by AlloVir, Inc. in conjunction with this event. For further details see: AlloVir (ALVR) Investor Presentation - Slideshow
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference in New York on Wednesday, S...
Gainers: Digital Media Solutions ( DMS ) +133% . FlexShopper ( FPAY ) +72% . Absci ( ABSI ) +58% . Timber Pharmaceuticals ( TMBR ) +50% . T2 Biosystems ( TTOO ) +37% . Wave Life Sciences ( WVE ) +36% . Veru ( VE...
Over the past few days, there have been some monster moves across a number of Russell 3,000 stocks. Taking a look at the Russell 3,000 members that had at least been cut in half from the time of the index’s high on January 3rd through the low on June 16th, followed by a rally o...
Gainers: CinCor Pharma CINC +66% . Karuna Therapeutics KRTX +61% . 23andMe ( ME ) +22% . Cerevel Therapeutics ( CERE ) +20% . Quoin Pharmaceuticals ( QNRX ) +16% . Losers: Reata Pharmaceuticals RETA -31% . uniQure QUR...
AlloVir press release ( NASDAQ: ALVR ): Q2 GAAP EPS of $0.69 beats by $1.42 . For the quarter ended June 30, 2022, net loss was $44.6 million or $0.69 per share, compared with a net loss of $37.6 million or $0.60 per share for the quarter ended June 30, 2021. For...
News, Short Squeeze, Breakout and More Instantly...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...